drugset / Trial / NCT04984330
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
Timeline
- Start
- 2021-12
- Primary completion
- 2023-06
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |